An interventional study of Artemisinin and Identical looking placebo capsule in Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-02-28.
Sponsored by Sheppard Pratt Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 657th largest by enrollment of the 1,320 interventional ones that give a count, is one of 68 that started in 2008, is one of 480 with no phase, and was the 426th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,466 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 68 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,320 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,466 have an industry lead sponsor. The 10 most frequent:
Sheppard Pratt Health System is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Sheppard Pratt Health System has 5 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,466 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
The aims of the current study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg artemisinin capsule
Dietary Supplement: Artemisinin
Identical looking placebo capsule
Dietary Supplement: Identical looking placebo capsule
100 mg of artemisinin twice per day for 10 weeks
Identical looking placebo twice per day for 10 weeks
Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale. PANSS positive symptom scores and negative symptom scores each range from 7 to 49 units on a scale.
Time frame: 10 weeks (weeks 2 & 12)
Change in Cognitive Functioning as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status and Change in Functional Performance as Measured by the UCSD Performance-based Skills Assessment.
Time frame: 10 weeks (weeks 2 & 12)
We enrolled n=66 participants drawn from the Sheppard Pratt Health System and from rehabilitation and treatment programs in Central Maryland. Dates of recruitment 8/08-1/10.
| Milestone | Artemisinin | Placebo |
|---|---|---|
| Started | 33 | 33 |
| Completed | 26 | 31 |
| Not completed | 7 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Other reason | 1 | 1 |
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale. PANSS positive symptom scores and negative symptom scores each range from 7 to 49 units on a scale.
| units on a scale | Artemisinin | Placebo |
|---|---|---|
| Week 2 PANSS total symptom score | 64 ± 8.74 | 68.13 ± 9.07 |
| Week 12 PANSS total symptom score | 61.42 ± 10.53 | 66.32 ± 9.45 |
| Week 2 PANSS positive score | 15.42 ± 4.18 | 16.26 ± 3.96 |
| Week 12 PANSS positive score | 14.92 ± 5.11 | 16.35 ± 5.35 |
| Week 2 PANSS negative score | 19.08 ± 3.12 | 19.77 ± 3.48 |
| Week 12 PANSS negative score | 18.69 ± 3.69 | 19.03 ± 3.67 |
| Week 2 PANSS general score | 29.5 ± 5.32 | 32.10 ± 6.18 |
| Week 12 PANSS general score | 27.81 ± 4.78 | 30.94 ± 4.84 |
Results for this outcome have not been posted.
Collected over 8/08-1/10. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Artemisinin | — | 3/33 (9.1%) | 0/26 (0%) |
| Placebo | — | 3/33 (9.1%) | 0/31 (0%) |
| Event | Artemisinin | Placebo |
|---|---|---|
| Schizophrenia exacerbationPsychiatric disorders | 2/33 | 2/33 |
| Arm fracture requiring hospitalizationMusculoskeletal and connective tissue disorders | 0/33 | 1/33 |
| Atypical chest painCardiac disorders | 1/33 | 0/33 |
| Age, Categorical(Participants) | Artemisinin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 33 | 66 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Artemisinin | Placebo | Total |
|---|---|---|---|
| Mean | 45.4 ± 9.0 | 49.2 ± 9.2 | 47.3 ± 9.3 |
| Sex: Female, Male(Participants) | Artemisinin | Placebo | Total |
|---|---|---|---|
| Female | 13 | 15 | 28 |
| Male | 20 | 18 | 38 |
| Region of Enrollment(participants) | Artemisinin | Placebo | Total |
|---|---|---|---|
| United States | 33 | 33 | 66 |
The record gives a start of Aug 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artemisinin
Sheppard Pratt Health System